HSP Research Foundation
Autumn Edition 2021
Winter edition to be published early June 2021
Implications for HSP and its treatment
Impaired cholesterol metabolism restored
Study of sporadic, late-onset cases
Marked differences between HSP types
Potential biomarker of disease progression
Some commonalities with Alzheimer’s
AD form with different disease mechanism
Research from China, Australia, Greece, the UK, Republic of Moldova, France, Cyprus, Italy, the USA, Japan, Sweden, Algeria, Portugal, Turkey, Belgium and India
What are the issues?
Get fit while you sit
Free online courses
Investigative drug approved
Planning & flexibility the secret
Improves spasticity & range of motion
Continuous technological innovation the key
Together we are strong
Drexel University team recipients
Independent Assessments the focus
Foundation Research Team
Fundraising for HSP Research
Securing the supply of drug treatments needed for the Phase 1 clinical trial is the current focus of the HSP Research Program. The aim of the clinical trials is to find an effective treatment for HSP.
There are technical, medical, ethical, regulatory, logistical, legal, financial and organisational challenges to address and take action on. The Foundation is fully committed to pushing ahead despite restrictions and limitations imposed by the global coronavirus pandemic.
Consistent funding support helps attract outside funding. The effort to get close to the target in 2020 is admirable in the circumstances – Thanks to those who gave! We need to reach $120,000 again in 2021 and need everyone’s support more than ever.
An effective treatment for HSP is now within reach!